文献速递临床生化临床免疫质量管理与危急值

循环瓜氨酸化蛋白作为肿瘤液体活检候选分析物

Circulating citrullinated proteins as candidate liquid biopsy analytes in cancer.
PubMed 文献 · Clin Chim Acta · 2026-10-16

本综述梳理了循环瓜氨酸化组蛋白H3(CitH3)、瓜氨酸化并经基质金属蛋白酶降解的波形蛋白(VICM)、肽酰精氨酸脱亚胺酶4(PAD4)及相关蛋白变体在肿瘤学中的功能,并讨论其作为液体活检分析物的适用性。CitH3证据最充分,部分肿瘤中具初步预后与疗效监测价值,但缺乏用于诊断、分层或微小残留病(MRD)监测的临床证据,目前应视为科研用/早期转化分析物。

要点

  • CitH3证据最充分,但NETs生物学及关联受情境与检测方法影响。
  • 部分肿瘤中具初步预后与疗效监测价值,诊断与MRD监测证据不足。
  • 检测异质性、基质效应、缺乏参考物质与EQA阻碍临床落地。

核心结论

  • 循环瓜氨酸化蛋白目前应视为科研用/早期转化分析物,而非可临床报告的肿瘤生物标志物。

研究设计与样本

  • 综述,覆盖血清和血浆中CitH3、VICM、PAD4及相关蛋白变体在肿瘤学中的证据。
  • 重点讨论血清和血浆ELISA、液相色谱-串联质谱(LC-MS/MS)、靶向蛋白质组学与生物传感器等技术。

主要发现

  • CitH3证据最充分,但中性粒细胞胞外诱捕网(NETs)生物学及其关联受情境与检测方法影响。
  • 核小体检测与游离组蛋白/游离肽检测测量的是不同分析物池。
  • 部分肿瘤中这些分析物具初步预后与治疗反应监测价值。
  • 缺乏用于肿瘤诊断、患者分层或微小残留病(MRD)监测的临床证据。

关键数值与推荐

  • 分析检测异质性、基质效应、缺乏有证参考物质、平台间可比性与协调性有限、缺乏外部质量评估(EQA)、缺乏经验证的临床cut-off hinder临床实施。
  • 关键分析前要求包括分析前控制、检测协调、参考物质/校准品/质控品/EQA材料的互换性评估,以及符合ISO 15189与体外诊断法规(IVDR)。

临床怎么用

  • 目前不宜作为临床可报告的肿瘤生物标志物用于诊断、分层或MRD监测。
  • 如用于研究,需关注分析前控制、检测协调与平台间可比性。

局限性

  • 血清和血浆证据与组织、骨髓、体外或临床前证据不同。
  • NETs生物学及关联受情境与检测方法影响,核小体与游离组蛋白/肽检测测量不同分析物池。
  • 检测异质性、基质效应、缺乏有证参考物质、平台间可比性有限、缺乏EQA与经验证cut-off限制临床实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review outlines the functions of circulating citrullinated histone H3 (CitH3), citrullinated and matrix metalloproteinase-degraded vimentin (VICM), peptidylarginine deiminase 4 (PAD4), and related proteoforms in oncology and discusses their suitability as analytes in liquid biopsies. Evidence in the serum and plasma is different from that in the tissue, bone marrow, in vitro, or preclinical evidence. Special emphasis has been placed on the following techniques: serum and plasma-based enzyme-linked immunosorbent assay (ELISA), liquid chromatography - tandem mass spectrometry (LC-MS/MS), targeted proteomics, and biosensors. Evidence is best established for CitH3, but the biology of neutrophil extracellular traps (NETs) and their reported associations are context- and assay-dependent, with nucleosomal assays and assays of free histones/free peptides measuring distinct pools of analytes. However, for some cancers, these analytes have preliminary prognostic and treatment-response-monitoring value, but there is a lack of evidence for their clinical use in cancer diagnosis, patient stratification, or minimal residual disease (MRD) monitoring. Assay heterogeneity, matrix effects, lack of certified reference materials, limited inter-platform comparability and harmonization, lack of external quality assessment (EQA), and lack of validated clinical cut-offs hinder clinical implementation. Key preanalytical requirements include preanalytical control, harmonization of assays, assessment of the commutability of reference materials, calibrators, control materials, and EQA materials, and compliance with the International Organization for Standardization (ISO) 15,189 and the In Vitro Diagnostic Regulation (IVDR). At present, citrullinated proteins should be considered as research use/early translational analytes, and not as clinically reportable oncology biomarkers.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Omer AB, Saleem S, Khan R, et al. Circulating citrullinated proteins as candidate liquid biopsy analytes in cancer. Clin Chim Acta. 2026. PMID: 42887665. doi:10.1016/j.cca.2026.122904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。